The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug
The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob Reynolds
6:10
WSJ Explains
News moves fast, and there's not always time to untangle the complex forces driving the day's biggest stories. WSJ Explains breaks down big market moves, business and economic trends, and scientific developments to help you stay ahead of the curve.